Loading...

TTNP TITAN PHARMACEUTICALS INC Accounting Changes 8-K Filing

TTN

TTNP

TITAN PHARMACEUTICALS INC

(TTNP)

2024 8-K

Show Summary

Summary

Equity Offerings

Merger of Equals

Equity Offerings

Nasdaq Compliance

Management Changes

Nasdaq Compliance Issues

Management Change

CEO Resignation

Merger Announcement

Resignations and Appointments

Restatement of Financial St...

Equity Issuance

Agreement with Brian Crowley

Compliance with Nasdaq list...

Resignation of Brian Crowley

Reverse Stock Split

Reverse Stock Split

Notice from Nasdaq

Board of Directors Election

Private Placement and Purch...

Asset Purchase Agreement

Asset Purchase Agreement

Annual Meeting of Stockholders

Delisting Notice

External Links:

Titan Pharmaceuticals Inc restates financial statements for the quarterly period ended September 30, 2023 due to an error in accounting, resulting in a material weakness in internal control over financial reporting.

AI Assistant

TITAN PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.